Clinical Trial Update: Study Evaluating Pyrotinib in Combination With Capecitabine In Patients With HER2 Positive Metastatic Breast Cancer [Phase 1]

View source ↗

Summary

This Phase 1 study assessed the safety and tolerability of combining Pyrotinib with Capecitabine in patients with HER2-positive metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)
• Xeloda (capecitabine)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Metastatic Breast Cancer | Phase 1 | Status: COMPLETED